CDEK
← All drugs Report issue

varicella zoster virus glycoprotein e antigen

Trade name: Shingrix

Vaccineapproved

Approved

Oct 20, 2017

A zoster vaccine is a vaccine that reduces the incidence of herpes zoster (shingles), a disease caused by reactivation of the varicella zoster virus, which is also responsible for chickenpox. — Wikipedia

Clinical trial activity

58 trials · 57 clinical orgs · 1 marketing orgs

Phase 1
20
Phase 2
24
Phase 3
8
Phase 4
16

Earliest trial started Jun 1, 2007 (NCT00492739)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Oct 20, 2017

    GlaxoSmithKline — Earliest FDA Approval

  3. Oct 20, 2017

    GlaxoSmithKline — NDA Organization

  4. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedOct 20, 2017

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • hz/su vaccine
  • varicella zoster virus glycoprotein e antigen
  • vzv vaccine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07205796Phase 2May 1, 2026Government of China
NCT07280741Phase 4Dec 3, 2025University of Sao Paulo
NCT07285265Phase 1May 27, 2025Abogen Biosciences Co. Ltd.
NCT06890416Phase 3Apr 4, 2025Pfizer
NCT06851832Phase 1/Phase 2 (Phase 2)Feb 16, 2025Ab&b Biotechnology Co., Ltd., Government of China
NCT06801509Phase 1/Phase 2 (Phase 2)Feb 15, 2025Sinocelltech Ltd.
NCT06763783Phase 4Dec 17, 2024GlaxoSmithKline, Region Skane
NCT06581575Phase 2Sep 20, 2024Immorna Biotherapeutics, Inc., Tigermed Consulting Co., Ltd
NCT06409494Phase 1Jul 15, 2024EuBiologics Co.,Ltd
NCT06375512Phase 1Jul 5, 2024Government of China
NCT06569823Phase 1/Phase 2 (Phase 2)Jun 17, 2024Dynavax Technologies Corporation
NCT06335849Phase 1Mar 27, 2024Government of China, Nucleus Network Ltd
NCT06262776N/AFeb 29, 2024Central Adelaide Local Health Network Incorporated, National Health and Medical Research Council, Australia, University of Adelaide, University of Sydney
NCT06162494Phase 4Dec 5, 2023Northwestern University, University of Cincinnati, University of Colorado
NCT05775718Phase 2Dec 1, 2023GlaxoSmithKline, University of Colorado, Denver
NCT05991427Phase 1Nov 7, 2023Canadian Center for Vaccinology, Tianjin Cansino Biotechnology Inc
NCT05718037Phase 1Aug 1, 2023Government of China, Wuhan BravoVax Co., Ltd.
NCT05966090Phase 3Jul 28, 2023GlaxoSmithKline
NCT05898464Phase 4Jun 27, 2023Seoul National University
NCT05879419Phase 4May 23, 2023GlaxoSmithKline, University of Sao Paulo
Showing 20 of 58 trials
Page 1 / 3

Organizations

Research & Development (57)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit11742014
Government of ChinaGovernment5322023
University of Colorado, DenverAcademic/Hospital4432014
National Institute of Allergy and Infectious Diseases (NIAID)Government3122019
University of GenevaAcademic/Hospital3322007
Boston UniversityAcademic/Hospital2112018
Dynavax Technologies CorporationFor profit2222022
Emory UniversityAcademic/Hospital2222019
National Heart, Lung, and Blood Institute (NHLBI)Government2222018
PfizerFor profit2222023
Region SkaneGovernment2212019
Seoul National UniversityAcademic/Hospital2222023
University of ColoradoAcademic/Hospital2022014
University of Sao PauloAcademic/Hospital2212023
Ab&b Biotechnology Co., Ltd.Academic/Hospital1112025
Abogen Biosciences Co. Ltd.For profit1112025
Baylor UniversityAcademic/Hospital1112014
Canadian Center for VaccinologyAcademic/Hospital1012023
Catholic University of KoreaAcademic/Hospital1012023
Centers for Disease Control and Prevention (CDC)Government1012021
57 organizations
Page 1 / 3

Marketing (1)

OrganizationOrg typeRelationshipDate
GlaxoSmithKlineFor profitNDAOct 20, 2017